Q3 EPS Forecast for Soleno Therapeutics Boosted by Analyst

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at Lifesci Capital increased their Q3 2026 earnings per share estimates for shares of Soleno Therapeutics in a report released on Wednesday, November 5th. Lifesci Capital analyst K. Dellorusso now anticipates that the company will earn $0.72 per share for the quarter, up from their previous estimate of $0.63. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.72) per share. Lifesci Capital also issued estimates for Soleno Therapeutics’ Q4 2026 earnings at $0.89 EPS.

Several other equities research analysts have also weighed in on the company. Oppenheimer increased their target price on Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Wednesday, October 8th. Robert W. Baird set a $121.00 target price on Soleno Therapeutics and gave the stock an “outperform” rating in a research report on Friday, July 11th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $106.00 target price (down from $123.00) on shares of Soleno Therapeutics in a research report on Wednesday. Finally, Wall Street Zen raised Soleno Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $114.50.

Soleno Therapeutics Stock Performance

SLNO stock opened at $46.87 on Thursday. The company has a current ratio of 15.13, a quick ratio of 15.01 and a debt-to-equity ratio of 0.21. The firm has a market cap of $2.49 billion, a P/E ratio of -11.32 and a beta of -2.92. Soleno Therapeutics has a 12-month low of $41.50 and a 12-month high of $90.32. The stock’s 50 day simple moving average is $63.20 and its 200 day simple moving average is $73.27.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.39. The firm had revenue of $66.02 million for the quarter, compared to analyst estimates of $47.46 million.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of SLNO. Raymond James Financial Inc. acquired a new position in shares of Soleno Therapeutics during the second quarter valued at $25,000. Nisa Investment Advisors LLC increased its holdings in shares of Soleno Therapeutics by 287.8% during the second quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after purchasing an additional 400 shares during the period. AlphaQuest LLC increased its holdings in shares of Soleno Therapeutics by 37.5% during the first quarter. AlphaQuest LLC now owns 983 shares of the company’s stock valued at $70,000 after purchasing an additional 268 shares during the period. Osaic Holdings Inc. increased its holdings in shares of Soleno Therapeutics by 97.7% during the second quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after purchasing an additional 423 shares during the period. Finally, KBC Group NV acquired a new position in shares of Soleno Therapeutics during the second quarter valued at $77,000. 97.42% of the stock is owned by institutional investors and hedge funds.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.